Document Detail


Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension.
MedLine Citation:
PMID:  22480725     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Randomized controlled trials have resulted in improved outcomes in pulmonary arterial hypertension; however, they are biased by stringent inclusion criteria, pre-specified patient sub-sets, and study durations. In addition, common practice is to start oral therapies ahead of the more potent and titratable prostanoid therapies, despite advanced disease states at diagnosis. The objectives of our prospective registry were to evaluate long-term effects on functional class, 6-minute walking distance, hemodynamics, and survival, and also long-term tolerability of first-line sub-cutaneous treprostinil, a prostacyclin analog, in patients with severe pulmonary hypertension. METHODS: Data were collected from patients with functional class III/IV pre-capillary pulmonary hypertension (Dana Point groups 1 and 4; mean right arterial pressure ≥ 10 mmHg, and/or cardiac index ≤ 2.2 liters/min/m(2)). Treprostinil dose adjustments were driven by clinical symptoms and side effects. RESULTS: The study included 111 patients (1999 to 2010). Of these, 13 (12%) stopped treatment prematurely because of drug side effects, 11 (9.9%) underwent double lung transplantation, and 49 (44.1%) died of any cause (41 on treatment, 8 after early drug discontinuation). Overall survival rates at 1, 5, and 9 years were 84%, 53%, and 33%. In patients who were able to tolerate treatment > 6 months, survival rates were 57% at 9 years. CONCLUSION: First-line treatment of severe pre-capillary pulmonary hypertension with sub-cutaneous treprostinil is safe and efficacious over many years. If up-titration beyond 6 months is tolerated, effective doses are reached and outcomes are good.
Authors:
Roela Sadushi-Koliçi; Nika Skoro-Sajer; Daniel Zimmer; Diana Bonderman; Michael Schemper; Walter Klepetko; Jutta Glatz; Johannes Jakowitsch; Irene Lang
Related Documents :
22284935 - D-dimer threshold increase with pretest probability unlikely for pulmonary embolism to ...
8412285 - Clinical studies on the mechanism for acupuncture stimulation of ovulation.
23523435 - The safety of spinal pedicle screws in children ages 1 to 12.
16835255 - Intra-articular magnesium is effective for postoperative analgesia in arthroscopic knee...
17302365 - Optimizing treatment outcomes in chronic hepatitis c: management of non-response.
3078275 - Effects of antihypertensive drugs on cardiovascular risk factors.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-3
Journal Detail:
Title:  The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation     Volume:  -     ISSN:  1557-3117     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-6     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9102703     Medline TA:  J Heart Lung Transplant     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
Affiliation:
Department of Internal Medicine II, Division of Cardiology, Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  IgG4-related disease and renal and urological involvement.
Next Document:  Odor compounds from different sources of landfill: Characterization and source identification.